StockWatch
·
Pharmaceutical Preparations
InvestmentNov 17, 2026, 04:50 PM

Protagenic Therapeutics Raises $1.5M in Private Placement

AI Summary

Protagenic Therapeutics, Inc. announced a private placement of securities, raising approximately $1.5 million in upfront gross proceeds, with potential for up to $5 million in total gross proceeds. The funds will be used for IND-enabling activities for PT00114, initiation of a Phase 1/2a clinical trial in Generalized Anxiety Disorder (GAD), and general corporate purposes. The company also provided an update on its PT00114 development, targeting IND submission in late Q1 2027 and first patient dosing in Q2 2027, with topline safety data expected in 2H 2027 and exploratory efficacy data in 1H 2028.

Key Highlights

  • Protagenic Therapeutics secured $1.5 million in upfront financing from a private placement, with up to $3.5 million more possible.
  • Proceeds will fund IND-enabling activities and the initiation of a Phase 1/2a clinical trial for PT00114 in Generalized Anxiety Disorder.
  • IND submission is targeted for late Q1 2027, with first patient dosing planned for Q2 2027.
  • Topline safety data for the Phase 1/2a trial is expected in the second half of 2027.
  • Exploratory efficacy data is anticipated in the first half of 2028.
  • The company received positive feedback from the FDA on its pre-IND package for PT00114.